tome.bioHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $245.57MM
Tome Biosciences is a genomic medicine company. By creating programmable gene insertion technology, Tome Biosciences has a mission to deliver patients a cure with cell technology. The company’s integrative gene therapies work by destroying deoxyribonucleic acid and inserting a genetic sequence at any location of any size. Tome Biosciences was founded by Jonathan Gootenberg and Omar Abudayyeh in 2021 and is headquartered in Boston, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
12/12/2023 | Series B | $150MM | $xx.xx | $435.54MM | Alexandria Venture Investments, Andreessen Horowitz, Arch Venture Partners, Bruker Corporation, Fujifilm Corporation, Gv, Longwood Fund, Polaris Partners | |
Price per Share
$xx.xx
Shares Outstanding
49,521,294
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Andreessen Horowitz, Arch Venture Partners, Bruker Corporation, Fujifilm Corporation, Gv, Longwood Fund, Polaris Partners
|
||||||
01/15/2022 | Series A | $29.69MM | $xx.xx | $313.13MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
24,306,564
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
01/15/2022 | Series A-2 | $65.88MM | $xx.xx | $313.13MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
26,971,260
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|